IVERIC Competitors

Delisted . USA . 
Stock . IVERIC Bio
ISEEDelisted Stock  USD 39.95  0.00  0.00%   
IVERIC Bio competes with Blueprint Medicines, Amylyx Pharmaceuticals, Day One, Immunovant, and Akero Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing IVERIC Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of IVERIC Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of IVERIC Bio competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of IVERIC Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
39.9539.9539.95
Details
Intrinsic
Valuation
LowRealHigh
31.4831.4843.95
Details
Naive
Forecast
LowNextHigh
39.1639.1639.16
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
39.9539.9539.95
Details

IVERIC Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between IVERIC Bio and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of IVERIC and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of IVERIC Bio does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AKRO
+ 0.9
AMLX
MDGL
+ 0.77
BPMC
ETNB
+ 0.71
MDGL
ETNB
+ 0.67
BPMC
PLRX
+ 0.67
DAWN
PLRX
+ 0.65
ETNB
  
High negative correlations   
APLS
- 0.7
AMLX
APLS
- 0.66
AKRO
KRTX
- 0.6
BPMC
APLS
- 0.55
KRTX
MDGL
- 0.55
KRTX
ETNB
- 0.53
KRTX

Risk-Adjusted Indicators

There is a big difference between IVERIC Stock performing well and IVERIC Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze IVERIC Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BPMC  1.84 (0.12)(0.03) 0.03  2.61 
(1.73)
 4.90 
(3.62)
 14.28 
AMLX  4.24  1.32  0.27  1.26  4.02 
(4.93)
 10.06 
(6.13)
 33.56 
KRTX  1.44  0.08 (0.04)(0.15) 1.67 
(1.46)
 3.38 
(2.71)
 10.01 
DAWN  2.10 (0.08)(0.03) 0.03  2.72 
(2.01)
 3.84 
(3.69)
 11.44 
IMVT  2.02 (0.35) 0.00 (0.18) 0.00 
 0.00 
 3.76 
(5.06)
 17.16 
AKRO  2.39  0.13  0.09  0.18  2.66 
(2.51)
 5.23 
(4.45)
 13.37 
MDGL  2.68  0.54  0.19  1.52  2.09 
(3.60)
 5.17 
(3.96)
 30.27 
APLS  2.39 (0.40) 0.00 (0.45) 0.00 
 0.00 
 4.31 
(5.17)
 15.97 
ETNB  2.79 (0.22) 0.00  0.04  3.29 
(3.41)
 5.19 
(6.35)
 27.43 
PLRX  2.71 (0.23)(0.03) 0.02  3.19 
(2.93)
 5.37 
(5.55)
 24.35 
All Fundamental Data

IVERIC Bio Competitive Analysis

The better you understand IVERIC Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, IVERIC Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across IVERIC Bio's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ISEE BPMC AMLX KRTX DAWN IMVT AKRO MDGL APLS ETNB
 0.00 
 39.95 
IVERIC
 2.56 
 94.15 
Blueprint
 1.54 
 5.27 
Amylyx
 0.71 
 203.11 
Karuna
 2.85 
 13.72 
Day
 1.24 
 26.87 
Immunovant
 4.90 
 32.73 
Akero
 5.53 
 347.45 
Madrigal
 10.88 
 30.77 
Apellis
 4.53 
 8.76 
89bio
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Slightly risky
Very steady
Not too volatile
Very steady
Very steady
Very steady
Very steady
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Solid
Very Weak
Very Weak
Very Weak
OK
OK
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Below Average
Low
Dangerous
About Average
Average
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Cautious Hold
Not Rated
Cautious Hold
Sell
Cautious Hold
Strong Hold
Sell
Strong Sell
Current Ratio
11.98
6.0
7.96
17.77
31.45
21.48
6.9
2.55
7.57
5.81
Net Asset
666.82 M
1.05 B
517.45 M
1.34 B
376.05 M
666.37 M
580.27 M
640.55 M
788.73 M
596.27 M
Profit Margin
N/A
-0.29
-1.32
N/A
-0.83
N/A
N/A
N/A
-0.35
N/A
EBITDA
(192.28 M)
(474.61 M)
39.89 M
(493.08 M)
(206.06 M)
(269.98 M)
(148.63 M)
(379.97 M)
(495.21 M)
(134.46 M)
Current Valuation
4.98 B
5.72 B
129.42 M
11.35 B
827.84 M
3.47 B
1.6 B
6.7 B
3.9 B
643.81 M
Price To Book
3.81
19.1
1.84
10.05
2.49
8.78
3.09
9.75
16.14
2.72
Operating Margin
N/A
-0.38
-181.88
-755.64
0.32
N/A
N/A
-1.87
-0.24
N/A
Retained Earnings
(864.81 M)
(2.34 B)
(304.95 M)
(997.89 M)
(458.58 M)
(825.68 M)
(574.1 M)
(1.34 B)
(2.84 B)
(457.43 M)
Current Asset
121.07 M
170.42 M
N/A
6.24 M
N/A
N/A
22.85 M
363.58 K
115.82 M
10.12 M
Beta
1.1
0.59
-0.7
1.15
-1.52
0.71
-0.26
-0.47
0.87
0.98
Number Of Employees
163
638
384
339
174
207
60
376
702
70
Equity Positions Weight
N/A
N/A
50.03
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
137.98 M
63.53 M
68.55 M
38.2 M
100.85 M
146.78 M
69.8 M
21.81 M
124.39 M
117.58 M
Cash Flow From Operations
(163.77 M)
(436.85 M)
11.92 M
(385.82 M)
(146.85 M)
(214.23 M)
(145.37 M)
(324.23 M)
(594.74 M)
(129.19 M)
Total Debt
97.77 M
774.12 M
4.24 M
16.69 M
408 K
138 K
26.3 M
117.19 M
110.93 M
27.11 M
Return On Equity
-0.55
-0.5
-0.84
-0.36
-0.18
-0.92
-0.36
-1.3
-1.07
-0.73
Z Score
32.19
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.3
-0.15
-0.43
-0.25
-0.25
-0.55
-0.23
-0.52
-0.16
-0.41
Number Of Shares Shorted
16.64 M
4.13 M
1.29 M
1.97 M
18.02 M
13.1 M
3.82 M
4.53 M
20.79 M
5.38 M
Book Value Per Share
3.48
4.93
2.86
32.94
5.51
3.06
10.61
35.64
1.94
3.56
Current Liabilities
14.54 M
18.64 M
N/A
8.73 M
N/A
N/A
859.05 K
49.28 M
5.13 M
3.89 M
Total Asset
666.82 M
1.05 B
517.45 M
1.34 B
376.05 M
666.37 M
580.27 M
640.55 M
788.73 M
596.27 M
Debt To Equity
0.007
0.14
0.036
0.015
0.002
0.004
0.072
0.6
0.63
0.13
Short Ratio
5.25
6.53
0.81
3.6
15.57
19.69
8.02
13.46
7.13
10.28
Target Price
39.1
125.58
7.5
324.17
37.0
48.93
48.27
372.2
45.75
30.13
Shares Owned By Institutions
99.35
99.1
82.46
86.32
93.1
54.57
94.66
91.44
97.46
93.66
Market Capitalization
5.51 B
5.98 B
361.25 M
12.6 B
1.38 B
3.94 B
2.28 B
7.58 B
3.83 B
1.03 B
Price To Earning
4.17
7.93
N/A
-19.88
3.88
N/A
-7.43
-13.96
-6.94
-1.04
Price To Earnings To Growth
N/A
N/A
-0.15
1.46
N/A
N/A
0.93
N/A
-0.3
-0.45
Price To Sales
N/A
13.77
1.84
19264.95
13.57
N/A
N/A
98.66
5.35
N/A
Net Income
(185.21 M)
(506.98 M)
49.27 M
(433.68 M)
(188.92 M)
(259.34 M)
(151.76 M)
(373.63 M)
(528.63 M)
(142.19 M)
Earnings Per Share
-1.82
-2.09
-3.82
-11.74
-0.97
-2.21
-3.78
-25.02
-2.03
-2.96
Shares Owned By Insiders
0.65
0.9
14.32
4.98
17.01
55.64
5.34
8.56
13.98
0.57
Revenue
N/A
249.38 M
380.79 M
654 K
N/A
N/A
N/A
N/A
396.59 M
N/A
Working Capital
627.24 M
593.47 M
382.62 M
1.25 B
345.77 M
617.16 M
540.83 M
518.73 M
518.74 M
563.92 M
Cash And Equivalents
311.96 M
853.11 M
206.68 M
407.41 M
394.86 M
427.2 M
180.72 M
211.77 M
852.8 M
193.34 M
Cash Per Share
2.64
14.28
3.53
13.6
5.38
3.66
4.81
12.38
7.76
4.16
Gross Profit
(117.01 M)
177.28 M
(74.21 M)
10.64 M
N/A
N/A
N/A
N/A
69.79 M
N/A
Day Typical Price
39.95
95.53
5.27
203.52
13.64
26.82
32.24
340.42
29.82
8.66
Accumulation Distribution
N/A
0.043
0.0463
0.0221
0.0453
0.0159
0.0577
0.0807
0.11
0.0685
Market Facilitation Index
N/A
4.23
0.25
4.56
0.63
0.43
1.9
28.34
3.28
0.61
Daily Balance Of Power
0.0
(0.58)
0.32
(0.32)
0.6032
0.7674
0.8053
0.6426
0.9207
0.623
Period Momentum Indicator
N/A
(2.47)
0.08
(1.46)
0.38
0.33
1.53
18.21
3.02
0.38
Rate Of Daily Change
1.0
0.97
1.02
0.99
1.03
1.01
1.05
1.06
1.11
1.05
Day Median Price
39.95
96.23
5.28
203.72
13.6
26.8
32.0
336.9
29.35
8.61
Price Action Indicator
N/A
(3.31)
0.035
(1.34)
0.32
0.24
1.49
19.65
2.93
0.34
Relative Strength Index
30.97
10.31
86.41
12.48
55.04
64.51
46.97
70.16
31.93
40.61
Coefficient Of Variation
357.62
6027.76
378.87
3440.45
7013.6
(1,386)
798.87
755.23
(1,111)
3108.62
Mean Deviation
1.24
1.84
4.24
1.44
2.1
2.02
2.39
2.68
2.39
2.79
Jensen Alpha
0.626
(0.12)
1.32
0.0833
(0.08)
(0.35)
0.1302
0.5441
(0.40)
(0.22)
Total Risk Alpha
0.2752
(0.37)
0.5816
(0.26)
(0.37)
(0.64)
(0.11)
(0.12)
(0.85)
(0.52)
Sortino Ratio
0.4257
(0.03)
0.2721
(0.04)
(0.03)
N/A
0.086
0.1927
N/A
3.0E-4
Downside Variance
1.5
7.38
24.1
3.04
7.99
N/A
9.13
5.96
N/A
11.54
Standard Deviation
2.34
2.55
5.56
1.92
2.52
2.75
3.12
4.54
3.41
4.1
Kurtosis
26.62
1.16
2.02
1.35
(0.40)
1.96
(0.26)
13.38
3.4
4.79
Potential Upside
2.45
4.9
10.06
3.38
3.84
3.76
5.23
5.17
4.31
5.19
Treynor Ratio
4.57
0.0253
1.26
(0.15)
0.0285
(0.18)
0.1835
1.52
(0.45)
0.0424
Maximum Drawdown
18.29
14.28
33.56
10.01
11.44
17.16
13.37
30.27
15.97
27.43
Variance
5.45
6.51
30.88
3.69
6.37
7.57
9.74
20.61
11.62
16.78
Market Risk Adjusted Performance
4.58
0.0353
1.27
(0.14)
0.0385
(0.17)
0.1935
1.53
(0.44)
0.0524
Risk Adjusted Performance
0.2212
0.0197
0.211
0.0283
0.0179
(0.05)
0.1035
0.1099
(0.06)
0.0328
Skewness
4.34
0.1604
0.4715
0.8553
(0.36)
0.1496
0.1632
3.09
0.4109
1.01
Semi Deviation
0.2541
2.61
4.02
1.67
2.72
N/A
2.66
2.09
N/A
3.29
Information Ratio
0.2236
(0.03)
0.2404
(0.04)
(0.04)
(0.12)
0.0833
0.1036
(0.13)
2.0E-4
Value At Risk
(1.52)
(3.62)
(6.13)
(2.71)
(3.69)
(5.06)
(4.45)
(3.96)
(5.17)
(6.35)
Expected Short fall
(1.44)
(1.73)
(4.93)
(1.46)
(2.01)
N/A
(2.51)
(3.60)
N/A
(3.41)
Downside Deviation
1.23
2.72
4.91
1.74
2.83
N/A
3.02
2.44
N/A
3.4
Semi Variance
0.0646
6.83
16.19
2.8
7.42
N/A
7.08
4.37
N/A
10.8

IVERIC Bio Competition Performance Charts

Five steps to successful analysis of IVERIC Bio Competition

IVERIC Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by IVERIC Bio in relation to its competition. IVERIC Bio's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of IVERIC Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact IVERIC Bio's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to IVERIC Bio, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your IVERIC Bio position

In addition to having IVERIC Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks
Soft Drinks Theme
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in IVERIC Stock

If you are still planning to invest in IVERIC Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the IVERIC Bio's history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY